

09992660

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPLUS
NEWS	23	May 27	CAPLUS super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS	EXPRESS		MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Kamal Saeed

09992660

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:05:41 ON 30 MAY 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:05:47 ON 30 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2004 HIGHEST RN 687134-56-1

DICTIONARY FILE UPDATES: 28 MAY 2004 HIGHEST RN 687134-56-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading 09992660.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Kamal Saeed

09992660

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 13:06:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 19971 TO ITERATE

100.0% PROCESSED 19971 ITERATIONS
SEARCH TIME: 00.00.01

28 ANSWERS

L2 28 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 13:06:21 ON 30 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 May 2004 VOL 140 ISS 23

FILE LAST UPDATED: 28 May 2004 (20040528/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 3 L2

=> d ibib abs hitstr tot


09992660

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2003:877311 CAPLUS
 DOCUMENT NUMBER: 140:128315
 TITLE: Synthesis and biological evaluation of benzazepine
 oxazolidinone antibacterials
 AUTHOR(S): Johnson, Paul D.; Aristoff, Paul A.; Zurenko, Gary
 E.:
 CORPORATE SOURCE: Schaadt, Ronda D.; Yagi, Betty H.; Ford, Charles W.;
 Hamel, Judith C.; Stapert, Douglas; Moerman, Judy K.
 Kalamazoo, MI, 49001, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
 13(23), 4197-4200
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Novel benzazepine oxazolidinone antibacterials were synthesized and
 evaluated against relevant susceptible and resistant organisms. The
 effect of ring nitrogen position and N-substitution on antibacterial
 activity is examd. Comps. thus tested included
 N-[(5S)-2-oxo-3-(2,3,4,5-
 tetrahydro-1H-1-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
 N-[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-5-
 oxazolidinyl]methyl]acetamide, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-2-
 (hydroxyacetyl)-1H-2-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
 and
 N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-
 oxazolidinyl]methyl]acetamide.
 IT 444587-56-8, N-[(5S)-3-(3-Formyl-2,3,4,5-tetrahydro-1H-3-
 benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-57-9
 N-[(5S)-2-Oxo-3-(2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-
 yl)-5-oxazolidinyl]methyl]acetamide 444587-58-0
 444587-60-4, N-[(5S)-3-(3-Acetyl-2,3,4,5-tetrahydro-1H-3-
 benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-61-5
 444587-62-6, N-[(5S)-3-(3-Benzoyl-2,3,4,5-tetrahydro-1H-3-
 benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-64-8
 N-[(5S)-2-Oxo-3-(2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-
 7-yl)-5-oxazolidinyl]methyl]acetamide 444587-67-1
 444587-68-2, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-(phenylacetyl)-
 1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (prepn. and antibacterial activity of
 N-[(oxo(tetrahydrobenzazepinyl)ox
 azolidinyl]methyl]acetamide derivs.)
 RN 444587-56-8 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-
 oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 444587-57-9 CAPLUS
 CN Acetamide, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-
 benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-58-0 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-
 3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-60-4 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-
 oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 444587-61-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-
 3-oxazolidinyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-62-6 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-
 oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-64-8 CAPLUS
 CN Acetamide, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-
 benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 444587-67-1 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-
 3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-68-2 CAPLUS
 CN Acetamide, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-
 benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 444588-27-6, N-[(5S)-2-Oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-
 7-yl)-5-oxazolidinyl]methyl]acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological
 study); RACT (Reactant or reagent)
 (prepn. and antibacterial activity of
 N-[(oxo(tetrahydrobenzazepinyl)ox
 azolidinyl]methyl]acetamide derivs.)
 RN 444588-27-6 CAPLUS
 CN Acetamide, N-[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-
 oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Kamal Saeed

09992660

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:696875 CAPLUS
 DOCUMENT NUMBER: 139:214457
 TITLE: Preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents
 INVENTOR(S): Thomas, Richard C.; Poel, Toni-Jo; Barbachyn, Michael R.; Gordeev, Mikhail F.; Luehr, Gary W.; Renslo, Adam;
 PATENT ASSIGNER(S): Singh, Upinder
 SOURCE: Pharmacia & Upjohn Company, USA
 DOCUMENT TYPE: PCT Int. Appl., 234 pp.
 LANGUAGE: CODEN: PIXXD2
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: Patent English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072553	A1	20030904	WO 2003-US3125	20030224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM, ZW, AA, AB, AD, AE, AG, AK, AL, AM, AN, AO, AP, AR, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GH, GI, GJ, GK, GL, GM, GN, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.				

US 2004044052 A1 20040304 US 2003-373286 20030224
 PRIORITY APPLN. INFO.: US 2002-359495P P 20020225
 OTHER SOURCE(S): MARPAT 139:214457
 GI

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. of formula I, II, and III [wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R₂; or BC = (un)substituted bicyclic heterocycle;

R₁ = H, OH, cycloalkyl, NH₂, or (un)substituted alkyl, alkoxy, or alkenyl;
 R₂ = independently H, NH₂, NO₂, CN, halo, or (un)substituted alkyl; with provisos; and pharmaceutically acceptable salts thereof) were prepd. as antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78.degree. for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of Staphylococcus aureus with MIC values ranging from 0.5 .mu.g/mL to 16 .mu.g/mL. Thus,

I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT 590422-67-6P, (5R)-3-(3-Formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxooxazolidine-5-carboxamide 590422-68-7P, (5R)-N-Methyl-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxooxazolidine-5-carboxamide 590422-69-8P, (5R)-3-[3-

(Hydroxyacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxooxazolidine-5-carboxamide 590422-70-1P, (5R)-N-Methyl-3-[3-(hydroxyacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxooxazolidine-5-carboxamide
 RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antibacterial agent; prepn. of aryloxazolidinecarboxamides and analogs as antibacterial agents)

RN 590422-67-6 CAPLUS
 CN 5-Oxazolidinecarboxamide,
 3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Kamal Saeed

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 590422-68-7 CAPLUS
 CN 5-Oxazolidinecarboxamide,
 3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590422-69-8 CAPLUS
 CN 5-Oxazolidinecarboxamide,
 2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-70-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, N-methyl-2-oxo-3-(2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09992660

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:575073 CAPLUS
DOCUMENT NUMBER: 137:140512
TITLE: Preparation of benzoheterocyclyloxazolidinones as antibacterial agents.
INVENTOR(S): Johnson, Paul D.; Aristoff, Paul A.; Poel, Toni-Jo; Thomasco, Lisa M.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059115	A1	20020801	WO 2001-US42944	20011114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, PT, SE, TR, BF, BZ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002133021	A1	20020919	US 2001-992660	20011114
EP 1337530	A1	20030827	EP 2001-997007	20011114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-249550P P	20001117
			WO 2001-US42944 W	20011114
OTHER SOURCE(S):		MARPAT 137:140512		
GI				



AB Title compds. [I: Y = NHC(W)R1, OZ, SZ, NH2; X = O, NR3, S, SO, SO2, S(O)(NR4); W = O, S; R1 = H, alkyl, cycloalkyl, alkoxy, alkylthio, amino; R2 = H, halo, alkyl; R3 = H, alkyl, aryl, Z, etc.; R4 = H, alkyl; Z = (substituted) (arom.) heterocyclyl; with provisos], were prepd. Thus, N-[(5S)-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methylacetamide (prepn. given) and NaHCO3 in THF were

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
treated with MeO2CCl with vigorous stirring. H2O was added and the mixt. was stirred 1 h to give Me (-)-6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate. The latter showed a min. inhibitory concn. of 1 µm.g/mL against Streptococcus pneumoniae SPNE9912.


IT 444587-56-8P 444587-57-9P 444587-58-0P
444587-59-1P 444587-60-4P 444587-61-5P
444587-62-6P 444587-63-7P 444587-64-8P
444587-65-9P 444587-66-0P 444587-67-1P
444587-68-2P 444587-69-3P 444587-70-6P
444587-71-7P 444587-72-8P 444587-73-9P
444587-74-0P 444587-75-1P 444587-76-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzoheterocyclyloxazolidinones as antibacterial agents)
RN 444587-56-8 CAPLUS
CN Acetamide,


N-[(5S)-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-57-9 CAPLUS
CN Acetamide, N-[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-58-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 444587-59-1 CAPLUS
CN Ethanethioamide,
N-[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-60-4 CAPLUS
CN Acetamide,
N-[(5S)-3-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-61-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Kamal Saeed


09992660

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 444587-62-6 CAPLUS
CN Acetamide, N-[[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-63-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-(5-amino-1,3,4-thiadiazol-2-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-64-8 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).




RN 444587-68-2 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-69-3 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-[5-(formylamino)-1,3,4-thiadiazol-2-yl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444587-70-6 CAPLUS
CN Acetamide, N-[[5-[7-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1,3,4-thiadiazol-2-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


Kamal Saeed

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry. Rotation (-).




RN 444587-65-9 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[5-(methylthio)-1,3,4-thiadiazol-2-yl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-66-0 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-67-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).




RN 444587-71-7 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[(4-iodophenyl)acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 444587-72-8 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-73-9 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[7-[(5S)-5-

09992660


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 [(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-7-yl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444587-74-0 CAPLUS
 CN Acetamide, N-[[[(5S)-2-oxo-3-[[2,3,4,5-tetrahydro-3-[[4-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-75-1 CAPLUS
 CN Acetamide, N-[[[(5S)-2-oxo-3-[[3-[[1,4-dioxopentyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 444587-76-2 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[[3-[[1,5-dioxohexyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444588-26-5P 444588-27-6P 444588-31-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzoheterocyclyloxazolidinones as antibacterial agents)
 RN 444588-26-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444588-27-6 CAPLUS


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Acetamide, N-[[[(5S)-2-oxo-3-[[2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444588-31-2 CAPLUS
 CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[[2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

09992660

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.71

170.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.08

-2.08

STN INTERNATIONAL LOGOFF AT 13:06:47 ON 30 MAY 2004